Vaccinex logo

VaccinexNASDAQ: VCNX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 August 2018

Next earnings report:

14 August 2024

Last dividends:

N/A

Next dividends:

N/A
$9.72 M
-88%vs. 3y high
17%vs. sector
-vs. 3y high
-vs. sector
-93%vs. 3y high
89%vs. sector
-89%vs. 3y high
93%vs. sector

Price

regular market | 25 min ago
$6.14-$0.04(-0.69%)

Dividend

No data over the past 3 years
$104.00 K-$3.90 M

Analysts recommendations

Institutional Ownership

VCNX Latest News

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease
globenewswire.com06 June 2024 Sentiment: POSITIVE

Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation,believed to be key drivers of neurodegeneration.

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com15 May 2024 Sentiment: NEUTRAL

Final patient completed their last visit in the SIGNAL-AD Phase 2a trial evaluating pepinemab for Alzheimer's Disease in early June 2024. $8.2 million of fresh funding was secured in the first quarter.

Why Is Vaccinex (VCNX) Stock Up 26% Today?
InvestorPlace06 October 2023 Sentiment: POSITIVE

Vaccinex (NASDAQ: VCNX ) stock is climbing higher on Friday after the clinical-stage biotechnology company announced insider buying. These insider trading actions were revealed by Vaccinex in a series of filings with the Securities and Exchange Commission (SEC).

Fcmi Parent Now Owns 42.8% of Vaccinex
24/7 Wall Street06 April 2023 Sentiment: NEGATIVE

Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX).

What type of business is Vaccinex?

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

What sector is Vaccinex in?

Vaccinex is in the Healthcare sector

What industry is Vaccinex in?

Vaccinex is in the Biotechnology industry

What country is Vaccinex from?

Vaccinex is headquartered in United States

When did Vaccinex go public?

Vaccinex initial public offering (IPO) was on 09 August 2018

What is Vaccinex website?

https://www.vaccinex.com

Is Vaccinex in the S&P 500?

No, Vaccinex is not included in the S&P 500 index

Is Vaccinex in the NASDAQ 100?

No, Vaccinex is not included in the NASDAQ 100 index

Is Vaccinex in the Dow Jones?

No, Vaccinex is not included in the Dow Jones index

When does Vaccinex report earnings?

The next expected earnings date for Vaccinex is 14 August 2024